NICE said it recommended Novartis's Zykadia to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with Pfizer's Xalkori (crizotinib). This follows a conditional approval of the drug last year by the EMA.
The drug was not recommended in earlier draft guidance due to "some uncertainties in the extent of treatment benefit," said...